Which statement best describes the general role of tumor markers in clinical practice?

Which statement best describes the general role of tumor markers in clinical practice?

• A. They are ideal for population screening
• B. They are highly specific for cancer
• C. They are useful for monitoring therapy and detecting recurrence
• D. They determine prognosis with high precision

Answer: (C)

Tumor markers are substances measured in blood or other fluids that reflect tumor activity. Their strongest value in everyday practice is tracking disease over time in patients with known cancer: how the level changes with treatment and whether there is evidence of recurrence during follow-up. When therapy works, marker levels often fall; rising levels can signal progression or relapse and prompt further imaging or treatment adjustment. They’re not reliable for population screening because many conditions outside cancer can raise marker levels, and not all cancers produce markers or do so consistently. This limits their usefulness as universal screening tests. They also don’t provide precise prognostic information—marker levels may correlate with tumor burden in some contexts, but they don’t determine prognosis with high accuracy. In clinical use, tumor markers are best applied as an adjunct to imaging and clinical assessment, often helping monitor treatment response and detect recurrence in cancers where a well-established marker exists.

Tumor markers are substances measured in blood or other fluids that reflect tumor activity. Their strongest value in everyday practice is tracking disease over time in patients with known cancer: how the level changes with treatment and whether there is evidence of recurrence during follow-up. When therapy works, marker levels often fall; rising levels can signal progression or relapse and prompt further imaging or treatment adjustment.

They’re not reliable for population screening because many conditions outside cancer can raise marker levels, and not all cancers produce markers or do so consistently. This limits their usefulness as universal screening tests. They also don’t provide precise prognostic information—marker levels may correlate with tumor burden in some contexts, but they don’t determine prognosis with high accuracy. In clinical use, tumor markers are best applied as an adjunct to imaging and clinical assessment, often helping monitor treatment response and detect recurrence in cancers where a well-established marker exists.